Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Pharmaceutical Assets Include Company's Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN)Company's Strategy is to Utilize the...
Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options